Greenphire Appoints Senior Director of Business Development in Europe

King of Prussia, PA – Greenphire, the leading provider of payment technologies for the clinical trials industry, today announced the extension of its presence in Europe with the appointment of Alex Livingstone. A seasoned industry executive, Alex brings more than 12 years of eClinical software, pharmaceutical and biotechnology industry experience to the company, in a move designed to help Greenphire extend its footprint in European markets.

Based in London, Alex will be responsible for developing market awareness of Greenphire's solutions and will lead the company's overall business development strategy in Europe. He joins Greenphire having previously served as Global Account Manager at Phase Forward (now Oracle), where he was charged with driving worldwide sales strategies. Previous to this role, he worked for G.D. Searle prior to its acquisition by Pfizer.

"Having admired Greenphire's achievements in the clinical payment technology field, its innovative nature and dynamic management team, I am delighted to have been chosen to lead the next stage of the company's development in Europe", comments Alex Livingstone. "I am excited to join a brand where innovation is valued  and the desire to change things for the better is at the core of its strategy."

Commenting on the new appointment, Greenphire CEO Sam Whitaker said, "Alex's extensive experience in the industry will be a tremendous asset to Greenphire at a time when we are developing quickly as a business. He will play a key role in capturing commercial opportunities in key markets across Europe and I am confident Alex will be a strong asset to Greenphire and our clients alike."

For further information on Greenphire and its innovative solutions please email: [email protected] or visit www.greenphire.com.

About Greenphire
Greenphire is the industry's leading provider of clinical payment technology, designed to change the way research professionals work. We leverage our proprietary workflow automation and advanced web‐based payment technologies to help our clients improve operational efficiency, reduce costs, mitigate regulatory risks, increase subject retention and compliance, and produce quantifiable results that improve clinical operations and strategic planning. Learn more at www.greenphire.com.

Suggested Articles

EQRx is adding a pair of PD-1/PD-L1 meds to its pipeline through a deal with CStone worth $150 million upfront but could net the latter $1.15 billion.

All eyes are on Pfizer’s COVID-19 vaccine work, but the Big Pharma has today quietly culled two midstage trials and one phase 1 test.

All subjects had lower extremity weakness after receiving antisense oligonucleotide GTX-102, leading Ultragenyx to pause the study.